SGPL1
Basic information
Region (hg38): 10:70815905-70958701
Links
Phenotypes
GenCC
Source:
- nephrotic syndrome 14 (Moderate), mode of inheritance: AR
- nephrotic syndrome 14 (Strong), mode of inheritance: AR
- nephrotic syndrome 14 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
RENI syndrome | AR | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Endocrine | Individuals have been described with immunodeficiency, including recurrent bacterial infections, and awareness may allow preventative measures and early and aggressive treatment of infections; Individuals have been described with hearing loss, and early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; Individuals have been described with adrenal insufficiency, and awareness may allow early diagnosis and management | Allergy/Immunology/Infectious; Audiologic/Otolaryngologic; Dermatologic; Endocrine; Genitourinary; Neurologic; Renal | 28165339; 28165343; 28181337; 36873630 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (10 variants)
- Pterin-4 alpha-carbinolamine dehydratase 1 deficiency (5 variants)
- Nephrotic syndrome 14 (3 variants)
- Nephrotic syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SGPL1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 62 | 69 | ||||
missense | 88 | 97 | ||||
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 5 | 8 | 1 | 14 | ||
non coding | 23 | 93 | 33 | 161 | ||
Total | 15 | 11 | 115 | 160 | 39 |
Highest pathogenic variant AF is 0.0000197
Variants in SGPL1
This is a list of pathogenic ClinVar variants found in the SGPL1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-70816859-T-C | Likely benign (Dec 18, 2023) | |||
10-70816859-T-TA | Nephrotic syndrome 14 | Pathogenic (Aug 24, 2023) | ||
10-70816887-C-A | Likely benign (Apr 22, 2022) | |||
10-70816895-G-C | Likely benign (Jan 16, 2024) | |||
10-70844458-C-T | Likely benign (Jun 15, 2021) | |||
10-70844477-C-T | Uncertain significance (May 25, 2022) | |||
10-70844489-A-G | Conflicting classifications of pathogenicity (Mar 20, 2024) | |||
10-70844506-G-T | Nephrotic syndrome 14 | Benign (Feb 01, 2024) | ||
10-70844513-C-G | Uncertain significance (Apr 26, 2022) | |||
10-70844517-A-C | Likely benign (Dec 22, 2023) | |||
10-70844518-A-G | Uncertain significance (Jun 13, 2022) | |||
10-70844531-AT-A | Nephrotic syndrome 14 | Likely pathogenic (Sep 17, 2018) | ||
10-70844532-T-C | Likely benign (Jul 31, 2023) | |||
10-70844555-A-G | Inborn genetic diseases | Uncertain significance (Apr 20, 2024) | ||
10-70844577-A-G | Likely benign (May 09, 2023) | |||
10-70844579-G-A | Pathogenic (Sep 15, 2022) | |||
10-70844587-G-A | Uncertain significance (Jan 29, 2024) | |||
10-70844589-G-T | Likely benign (Nov 18, 2022) | |||
10-70844591-G-A | Inborn genetic diseases | Likely pathogenic (May 17, 2024) | ||
10-70844598-G-A | SGPL1-related disorder | Likely benign (Jan 24, 2024) | ||
10-70844610-G-A | Pathogenic (Feb 11, 2022) | |||
10-70844611-G-T | Pathogenic (Nov 15, 2023) | |||
10-70844616-T-C | Likely benign (Sep 12, 2022) | |||
10-70844627-T-G | Uncertain significance (May 09, 2023) | |||
10-70844637-G-C | Uncertain significance (Jul 23, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SGPL1 | protein_coding | protein_coding | ENST00000373202 | 14 | 65214 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00363 | 0.996 | 125708 | 0 | 40 | 125748 | 0.000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.82 | 227 | 318 | 0.713 | 0.0000170 | 3726 |
Missense in Polyphen | 53 | 112.91 | 0.46941 | 1301 | ||
Synonymous | 0.285 | 111 | 115 | 0.966 | 0.00000618 | 1072 |
Loss of Function | 3.45 | 10 | 30.6 | 0.326 | 0.00000155 | 381 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000133 | 0.000133 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.000878 | 0.000878 |
European (Non-Finnish) | 0.0000985 | 0.0000967 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Cleaves phosphorylated sphingoid bases (PSBs), such as sphingosine-1-phosphate, into fatty aldehydes and phosphoethanolamine. Elevates stress-induced ceramide production and apoptosis. {ECO:0000269|PubMed:11018465, ECO:0000269|PubMed:14570870, ECO:0000269|PubMed:24809814, ECO:0000269|PubMed:28165339}.;
- Pathway
- Sphingolipid signaling pathway - Homo sapiens (human);Sphingolipid metabolism - Homo sapiens (human);Sphingolipid Metabolism;Gaucher Disease;Globoid Cell Leukodystrophy;Metachromatic Leukodystrophy (MLD);Fabry disease;Krabbe disease;Sphingolipid Metabolism;Kennedy pathway from Sphingolipids;Metabolism of lipids;Metabolism;Glycosphingolipid metabolism;Sphingolipid de novo biosynthesis;Sphingolipid metabolism;Sphingosine 1-phosphate (S1P) pathway
(Consensus)
Recessive Scores
- pRec
- 0.432
Intolerance Scores
- loftool
- 0.593
- rvis_EVS
- -0.29
- rvis_percentile_EVS
- 33.34
Haploinsufficiency Scores
- pHI
- 0.165
- hipred
- Y
- hipred_score
- 0.601
- ghis
- 0.567
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.554
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sgpl1
- Phenotype
- growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; renal/urinary system phenotype; skeleton phenotype; respiratory system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; reproductive system phenotype; digestive/alimentary phenotype; immune system phenotype;
Gene ontology
- Biological process
- luteinization;vasculogenesis;ameboidal-type cell migration;kidney development;fatty acid metabolic process;sphingolipid metabolic process;ceramide metabolic process;spermatogenesis;androgen metabolic process;estrogen metabolic process;post-embryonic development;fibroblast migration;hemopoiesis;sphingolipid biosynthetic process;sphingolipid catabolic process;Leydig cell differentiation;regulation of multicellular organism growth;platelet-derived growth factor receptor signaling pathway;skeletal system morphogenesis;roof of mouth development;face morphogenesis;apoptotic signaling pathway
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;integral component of endoplasmic reticulum membrane
- Molecular function
- protein binding;sphinganine-1-phosphate aldolase activity;carboxy-lyase activity;pyridoxal phosphate binding